|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
71.100 -1.150 (-1.592%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 5,538,812 | 57.168% | 3,524,143 | 2,364,445 | 1,552,486 | 1,190,479 |
| Cost of Sales | (991,897) | 71.904% | (577,006) | (369,205) | (198,149) | (183,410) |
| Gross Profit | 4,546,915 | 54.282% | 2,947,137 | 1,995,240 | 1,354,337 | 1,007,069 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (92) | -- | 700 | (614) | (326) | 2,479 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (3,601) | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 2,457,754 | 40.838% | 1,745,089 | 1,177,749 | 972,917 | 973,242 | |
| Taxation | (396,027) | 33.393% | (296,887) | (176,163) | (144,785) | (146,757) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 620 | -82.540% | 3,551 | 439 | 0 | (35) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,062,347 | 42.059% | 1,451,753 | 1,002,025 | 828,132 | 826,450 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (111,108) | 134.509% | (47,379) | (13,138) | (9,408) | (9,882) |
| Depreciation & Amortisation | 49,486 | 44.802% | 34,175 | 27,628 | 24,210 | 22,291 |
| Directors' Emoluments | -- | -- | 16,596 | 14,161 | 13,099 | 2,752 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 210.000 | 40.940% | 149.000 | 99.000 | 83.000 | -- |
| DPS (cts) | 119.420 | -- | 89.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | 56.867% | -- | 59.732% | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.687 | 1.325 | 0.710 | -- |
| NBV per share ($) | 6.913 | -- | 4.384 | 2.848 | -- | -- |
| Remarks: | Real time quote last updated: 02/04/2025 10:05 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,062,347 |
| %Change | 42.059% |
| EPS / (LPS) | RMB 2.100 |
| NBV Per Share (¥) | RMB 6.913 |